(Circulation. 1996;93:457-462.)
© 1996 American Heart Association, Inc.
Articles |
From the Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Stacy F. Davis, MD, Brigham and Women's Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115.
| Abstract |
|---|
|
|
|---|
Methods and
Results Endothelium-dependent
vasomotion was assessed early posttransplant in 20 patients by serial
intracoronary acetylcholine infusion, and the percent
change in diameter was measured by quantitative angiography. The
development of arteriosclerosis was studied by use
of intravascular ultrasound in the same 20 patients by quantifying the
changes in intimal index (
Ii) and maximal intimal thickness
[
Mt] of 46 matched coronary segments between initial and
1-year follow-up studies. Coronary segments with
endothelial dysfunction (constriction
5%; n=23)
demonstrated a significantly greater increase in mean Ii and Mt by 1
year posttransplant compared with segments with normal
endothelial function (n=23) (
Ii=7±2% versus
2±1%
[P<.05] and
Mt=140±40 versus
50±20 µm
[P<.05]). No other parameters examined
predicted the development of allograft
arteriosclerosis in the initial year
posttransplant.
Conclusions Paired studies that used intravascular ultrasound showed that early endothelial dysfunction predicts the development of allograft arteriosclerosis during the initial year posttransplant. This early pathophysiological feature is likely an important marker that could be useful in therapeutic trials.
Key Words: endothelium acetylcholine ultrasonics transplantation atherosclerosis
| Introduction |
|---|
|
|
|---|
Endothelial dysfunction is an early and characteristic feature of both native and allograft coronary artery disease.9 10 11 12 It would be helpful if this pathophysiological marker could be used in transplant patients to detect early disease activity before the occurrence of significant vessel wall disease. Thus, the aim of the present study was to identify early endothelial dysfunction in transplant recipients and correlate this with the later development of intimal pathology. We hypothesized that early evidence of endothelial dysfunction after cardiac transplantation would predict the development and subsequent progression of accelerated allograft arteriosclerosis.
| Methods |
|---|
|
|
|---|
All patients were treated with triple immunosuppression (cyclosporine, prednisone, and azathioprine) and two patients in the study group received OKT3 induction therapy. The clinical characteristics of each patient were obtained, including the pretransplant diagnosis, age, and sex of the recipient and donor, graft ischemic time, pretransplant and posttransplant risk factors for native coronary atherosclerosis, cytomegalovirus serologies, serum lipid profiles, posttransplant hyperlipidemic therapy, and the number of treated rejection episodes.
Study Protocol
Written informed consent was obtained from
patients before
cardiac catheterization in accordance with the
guidelines established by the Committee for the Protection of Human
Subjects. Long-acting vasoactive medications, including calcium
channel blockers, ß-blockers, nitrates, and
angiotensin-converting enzyme inhibitors,
were discontinued at least 18 hours before the baseline
catheterization. After the left heart
catheterization was performed, patients were enrolled
in the study if their LAD was free of any sites with >50%
stenosis.
Intracoronary Infusions
Serial intracoronary
infusions were performed
according to an established protocol: (1) control infusion (dextrose
5% in water [D5W]); (2) serial 2.5-minute infusions of the
endothelium-dependent vasodilator acetylcholine
(Miochol, Iolab Pharmaceuticals) with final estimated
intracoronary concentrations of
10-8,
10-7, and
10-6 mol/L (based on assumed LAD blood
flow of 80 mL/min)13 ; (3) 5-minute repeat control infusion
of D5W; and (4) 3-minute infusion of the
endothelium-independent vasodilator
nitroglycerin at 16 µg/min.9 During each
infusion, blood pressure, heart rate, and ECG were continuously
monitored. Cineangiographic images were obtained after each
infusion.
IVUS
After removal of the infusion
catheter, the
intracoronary imaging system was passed into the LAD.
Sublingual nitroglycerin (0.4 mg) was given before
insertion of the catheter. The imaging system consisted of a 30-MHz
transducer and rotating mirror enclosed within an acoustic housing at
the tip of a 4.3F, 135-cm-long catheter (CVIS Inc).14
The imaging catheter was advanced as far distal as possible into the
LAD. Contrast cineangiography was used to record each IVUS catheter
position. A map was created by printing a video image of the LAD on
heat-sensitive paper. Each IVUS position and its relationship to
adjacent anatomic landmarks, such as diagonal or septal perforator
branches, was identified by review of video loops and clearly marked on
the paper for subsequent reference. A second IVUS study, performed 1
year later, used this map and angiographic landmarks to carefully match
catheter positions.
Analysis
IVUS Measurements
IVUS images were
recorded on Super VHS tape and digitized
into a Macintosh computer for quantitative analysis.
Forty-six coronary segments with matched IVUS data from
serial studies were analyzed. Matching of segments was
confirmed by review of the angiogram and IVUS catheter position
maps.
The ultrasound images at each position were assessed by two
observers
blinded to the results of the acetylcholine infusion. The lumen and
lumen/intima interface were planimetered, intimal thickening was
measured at eight radial chords, and the maximal intimal thickness (Mt)
was recorded. Development of intimal pathology was quantified by
measuring the change in intimal index (Ii) [Ii=intimal
area/(intimal
area+luminal area)] and Mt (
Mt) of the matched coronary
segments between initial and 1-year follow-up studies. The results
of three digitized frames at each position were averaged to obtain the
data for that segment. Segments were included if they had analyzable
matched ultrasound data and baseline vasomotion data. Progression of
intimal pathology between initial and 1-year follow-up IVUS studies
was defined as a mean
Ii
5% or a mean
Mt
150 µm.
Quantitative Coronary Angiography
Technically
suitable single-plane angiographic images were
selected for computer analysis based on a previously validated
method.10 15 The variability of this method is
<4%.16 17 An automated edge-detection program was
used to search densities and seek inflection points, measuring the
diameter of the vessel along the selected segment (Quantum IC Software,
ImageComm). To ensure accurate matching of coronary structure
and vasomotion, quantitative angiographic measurements from the
immediate region (4 to 5 mm) on both sides of each IVUS position were
used to assess endothelial function. The sites of
correlation were at least 1 cm apart within the artery.
Results of
endothelial function testing with
acetylcholine were analyzed on a per patient and a per segment
basis. Patients were categorized as constrictors
(endothelial dysfunction) if at least one
coronary segment demonstrated
5% constriction to
intracoronary acetylcholine infusion and as dilators
(normal endothelial function) if all vessel diameters
measured remained unchanged or dilated. Similarly, coronary
segments that demonstrated
5% constriction in response to
intracoronary acetylcholine infusion were defined as
constrictors, whereas those segments that remained unchanged or dilated
were categorized as dilators.
Statistics
For the per patient analysis, differences in the
demographic and clinical characteristics between groups of patients
were analyzed by use of unpaired t tests. A
univariate analysis of the individual clinical
parameters was performed. For the per segment
analysis, proportions of segments were analyzed by use
of Fisher's exact test. Statistical significance was defined as a
two-sided probability value less than .05. All data are expressed
as mean±SE.
| Results |
|---|
|
|
|---|
|
|
Patient Analysis: Coronary Structure and
Endothelial Function
The mean percent diameter change in response to
acetylcholine of
the 12 constrictors was -22.1±3.3% and the mean response of the
8 dilators was 7.9±2.0% (P<.01). There was no significant
difference between groups in response to infusion of the
endothelium-independent agonist
nitroglycerin (mean diameter change=12.0±3.9% versus
13.5±4.2% for constrictors versus dilators; P=NS).
The development of intimal thickening during the initial year
posttransplant was first analyzed on a per patient basis. There
was no significant difference in the baseline intimal thickness of the
12 constrictors compared with the 8 dilators. There was a trend showing
development of more intimal thickening among constrictors compared with
dilators during the initial year posttransplant (
Ii=9±3%
versus
4±1%, respectively, P=.10;
Mt=160±40
versus 70±20
µm, respectively, P=.09) (Table 3
).
|
In the present longitudinal study, early endothelial dysfunction (16±1 days posttransplant) tended to be associated with angiographic evidence of allograft arteriosclerosis at 1 year posttransplant. Seven (58%) of 12 patients with a constrictor response to acetylcholine early posttransplant demonstrated angiographic evidence of allograft arteriosclerosis at 1 year posttransplant (tapering of the distal LAD and/or tertiary vessel loss), in contrast to 1 (13%) of 8 patients with a dilator response (P=.05).
Segment Analysis: Coronary Structure and
Endothelial Function
Because segmental heterogeneity may occur within
a
patient's arteries and is characteristic of
arteriosclerosis, analyses and correlation
of coronary structure and endothelial function
were also performed on a per segment basis. A total of 46
coronary segments were analyzed. Twenty-three
segments (50%) demonstrated early endothelial
dysfunction (constriction to acetylcholine) with a mean diameter change
of -23.9±2.6% compared with a mean diameter change of
7.1±1.5% (P<.01) for the 23 (50%) segments with
preserved endothelial function. There was no
significant difference in the response of acetylcholine constrictor and
dilator segments to infusion of the
endothelium-independent agonist
nitroglycerin (mean diameter change=10.2±3.3% versus
13.4±2.6% for constrictors versus dilators).
There was no
significant difference in baseline intimal thickness of
the two groups of segments. The proportions of segments that
demonstrated progression of intimal thickening between initial and
1-year follow-up IVUS studies were analyzed. Progression of
Ii (
Ii
5%) occurred in 10 (43%) of 23 constricting segments and 5
(22%) of 23 dilators. Progression of Mt (
Mt
150 µm) occurred in
9 (39%) of 23 constrictors and 4 (17%) of 23 dilating segments.
We then
examined the percent change in mean Ii and Mt of the
constricting and dilating segments. The constricting segments
demonstrated a significantly greater change in mean Ii (
Ii)
and Mt (
Mt) by 1 year posttransplant compared with segments that
dilated in response to acetylcholine (
Ii=7±2% for
constrictors
versus 2±1% for dilators, P<.05;
Mt=140±40 µm for
constrictors versus 50±20 µm for dilators, P<.05)
(Table 4
).
|
In this segment analysis, only early posttransplant endothelial dysfunction predicted the development of intimal thickening by IVUS. The development of intimal thickening was not predicted by donor characteristics, graft ischemic time, recipient risk factors for native coronary atherosclerosis, the number of treated rejection episodes, or the immunosuppressive regimen.
| Discussion |
|---|
|
|
|---|
Allograft arteriosclerosis is insidious and progressive, begins early after transplantation, and is the chief cause of late mortality or retransplantation among adult and pediatric allograft recipients.18 19 Pathological studies20 demonstrated a diffuse myointimal proliferative process that affects epicardial vessels as well as the coronary microvasculature. In the earliest stages of development, this vasculopathy is often difficult to detect by angiography because the presence of intimal atheroma may be masked by compensatory vascular growth and dilation due to enlargement of the medial and adventitial layers.21 IVUS has become the primary modality for assessment of this disease, although the long-term significance of early intimal thickening is unclear.22 Identification of patients early posttransplantation who are at increased risk of accelerated allograft coronary arteriosclerosis has not been possible.
The coronary endothelium releases nitric oxide, which modulates vascular tone and permeability, inhibits platelet aggregation and smooth muscle cell proliferation, and regulates leukocyte adhesion.23 24 Abnormalities in the L-argininenitric oxide system likely play a role in the pathogenesis of native and allograft coronary artery disease.9 10 12 The coronary vasomotor response to acetylcholine is mediated via nitric oxide, and an abnormal response (constriction) is one hallmark of impaired endothelial function.25 Impaired coronary vasodilation in response to intracoronary acetylcholine infusion was described initially in epicardial vessels at 1 and 2 years after cardiac transplant.11 Treasure and colleagues26 extended these observations by demonstrating that endothelial dysfunction also occurred in the microvasculature of transplant recipients.
Endothelial dysfunction early after transplantation is a common feature of allograft arteriosclerosis that may be related to immune or ischemic endothelial injury in the setting of hyperlipidemia.7 11 Hruban and coworkers27 demonstrated T-lymphocytemediated endothelial activation in patients with this disease, suggesting that cellular immunity may promote endothelial injury. Cytotoxic B-cell antibodies, anti-HLA antibodies, and anti-endothelial antibodies also were demonstrated in patients with allograft arteriosclerosis.28 29 30 31 In addition to these immunologic observations, ischemia and reperfusion produced endothelial dysfunction in a canine cardiac allograft model, and peritransplant ischemic injury predicted the development of allograft arteriosclerosis in human recipients.32 33 This experimental evidence provides the rationale for our study of early posttransplant endothelial function.
We recently demonstrated34 that endothelial dysfunction occurred in approximately two thirds of patients within 1 month of transplant and was not predicted by donor or recipient demographics. The long-term significance of these findings has not been addressed previously. In another study,35 we tested endothelial function in 38 patients at 1 year posttransplant and found that the acetylcholine constrictors and dilators did not differ in the number of ischemic events over a 4-year period. IVUS data were not available in these patients.
The present longitudinal study used serial paired IVUS studies as a more rigorous measure of the development of allograft arteriosclerosis. Coronary segments with early endothelial dysfunction demonstrated a significantly greater increase in mean Ii and Mt by 1 year posttransplant compared with segments with preserved coronary vasomotion. Early endothelial dysfunction was the only predictor of the development of intimal thickening during the initial year posttransplant and may serve as a marker that could identify patients at increased risk of allograft coronary arteriosclerosis.
Study Limitations
The coronary vasodilator response to
acetylcholine was the
only measure of endothelial function examined in the
present study. We chose to focus on this response because it is an
accepted early measure of endothelial function,
reflects nitric oxidedependent pathways, and is
reproducible.36 Other manifestations of
endothelial injury, such as impaired
leukocyteendothelial cell interactions,
platelet hyperaggregability, and altered hemolytic and fibrinolytic
pathways also may occur posttransplant, but these were not
evaluated.37 38 39
The present longitudinal study matched early posttransplant coronary acetylcholine responses with serial IVUS images from a limited number of patients. Because segmental heterogeneity may occur within a patient and intimal thickening may not be uniformly distributed along the entire length of an artery, we analyzed endothelial function and coronary structure on a per segment basis. The length of thickening may correlate better with endothelial function than with the intimal pathology at a single position, but current technical limitations preclude accurate measurements of an entire region. The IVUS data presented in this study were based on images from the proximal one half to two thirds of the LAD because of limitations of the imaging technology. Other coronary vessels were not assessed because allograft arteriosclerosis is a diffuse process that tends to affect the entire coronary tree.40
Some intimal thickening may have developed between the time of cardiac transplantation and the initial IVUS study (16±1 days posttransplant). For the purpose of the present study, we assumed that the early posttransplant IVUS study accurately reflected baseline intimal pathology. Since the baseline Ii and Mt of the constrictor and dilator segments did not differ significantly, this did not influence our analysis.
We cannot exclude the possibility that constrictors have more baseline intimal thickening than dilators. Part of the early endothelial dysfunction observed may be related to donor-acquired atherosclerosis. However, the majority of patients with early endothelial dysfunction have no intimal thickening, and the contribution of early endothelial dysfunction due to cardiac transplantation cannot be underestimated.6
Conclusions
With the use of IVUS, the present longitudinal
study of
cardiac transplant patients has shown that early
endothelial dysfunction predicts the development of
allograft arteriosclerosis during the initial year
posttransplant. Endothelial dysfunction is an early
pathophysiological feature of transplant
coronary arteriosclerosis and is likely an
important marker and potential target for therapeutic
interventions.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
We wish to thank the dedicated research fellows and cardiologists who performed these catheterization studies over the past 4 years. We also wish to thank the technical and nursing staff of the cardiac catheterization laboratory who made these studies possible.
Received April 3, 1995; revision received August 7, 1995; accepted September 18, 1995.
| References |
|---|
|
|
|---|
2. Alderman EL, Wexler L. Angiographic implications of cardiac transplantation. Am J Cardiol. 1989;64:16E-21E. [Medline] [Order article via Infotrieve]
3.
Silverman JF, Lipton MJ, Graham A, Harris S, Wexler
L. Coronary arteriography in long-term human cardiac
transplantation survivors. Circulation. 1974;50:838-843.
4. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in heart transplant patients: coronary arteriographic findings. J Am Coll Cardiol. 1988;12:334-340. [Abstract]
5.
St Goar FG, Pinto FJ, Alderman EL, Valantine HA,
Schroeder JS, Gao SZ, Stinson EB, Popp RL.
Intracoronary ultrasound in cardiac transplant recipients:
in vivo evidence of `angiographically silent' intimal
thickening. Circulation. 1992;85:979-987.
6.
Anderson TJ, Meredith IT, Uehata A, Mudge GH, Selwyn
AP, Ganz P, Yeung AC. Functional significance of intimal
thickening detected by intravascular ultrasound early and late after
cardiac transplantation. Circulation. 1993;88:1093-1100.
7. Libby P, Salomon RN, Payne DD, Schoen FJ, Pober JS. Functions of vascular wall cells related to the development of transplant-associated coronary arteriosclerosis. Transplant Proc. 1989;21:3677-3684. [Medline] [Order article via Infotrieve]
8. Salomon RN, Hughs CW, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated evidence for chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791-798. [Abstract]
9. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051. [Abstract]
10.
Vita JA, Treasure CB, Nabel EG, McLenachan JM, Ludmer
PL, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P.
Coronary vasomotor response to acetylcholine relates to risk
factors for coronary artery disease.
Circulation. 1990;81:491-497.
11. Fish RD, Nabel EG, Selwyn AP, Ludmer PL, Mudge GH, Alexander RW, Ganz P. Responses of the coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest. 1988;81:21-31.
12. Yeung AC, Anderson TJ, Meredith IT, Uehata A, Ryan TJ Jr, Selwyn AP, Mudge GH, Ganz P. Endothelial dysfunction in the development and detection of transplant coronary artery disease. J Heart Lung Transplant. 1992;11:S69-S73. [Medline] [Order article via Infotrieve]
13.
Ganz W, Tamura K, Marcus HS, Donoso R, Yoshida S, Swan
HJC. Measurements of coronary sinus blood flow by
continuous thermodilution in man.
Circulation. 1971;44:181-195.
14.
Fitzgerald PJ, St Goar FG, Conolly AJ, Pinto FJ,
Billingham ME, Popp RL, Yock PG. Intravascular ultrasound
imaging of the coronary arteries: is three layers the
norm? Circulation. 1992;86:154-158.
15. Kirkeedie RL, Fung P, Smalling RW, Gould RL. Automated evaluation of vessel diameter from arteriograms. IEEE Trans Comput Soc Comput Cardiol. 1982;215-218.
16.
Mancini GBJ, Simon SB, McGillem MJ, LeFree MT, Friedman
HZ, Vogel RA. Automated quantitative coronary
arteriography: morphologic and physiologic validation in vivo of a
rapid digital angiographic method.
Circulation. 1987;75:452-460.
17. Skelton TN, Kisslo KB, Mikat EM, Bashore TM. Accuracy of digital angiography for quantitation of normal coronary luminal segments in excised, perfused hearts. Am J Cardiol. 1987;59:1261-1265. [Medline] [Order article via Infotrieve]
18.
Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A,
Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of
coronary artery disease in cardiac transplant patients
receiving immunosuppression therapy with cyclosporine and
prednisone. Circulation. 1987;76:827-834.
19. Pahl E, Zales VR, Fricker FJ, Addonizio LJ. Posttransplant coronary artery disease in children: a multicenter national survey. Circulation. 1994;90(pt 2):II-56-II-60.
20. Johnson DE, Alderman EL, Schroeder JS, Gao SZ, Hunt S, DeCampli WM, Stinson E, Billingham M. Transplant coronary artery disease: histopathologic correlations with angiographic morphology. J Am Coll Cardiol. 1991;17:449-457. [Abstract]
21. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375. [Abstract]
22.
Pinto FJ, Chenzbraun A, Botas J, Valantine HA, St Goar
FG, Alderman EL, Oesterle SN, Schroeder JS, Popp RL. Feasibility
of serial intracoronary ultrasound imaging for assessment
of progression of intimal proliferation in cardiac transplant
recipients. Circulation. 1994;90:2348-2355.
23.
Lowenstein CJ, Dinerman JL, Snyder SH. Nitric
oxide: a physiologic messenger. Ann Intern Med. 1994;120:227-237.
24. Gimbrone MA Jr, Bevilacqua MP, Cybulsky MI. Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann N Y Acad Sci. 1990;598:77-85. [Medline] [Order article via Infotrieve]
25.
Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri
A. Effect of inhibition of nitric oxide synthesis on epicardial
coronary artery caliber and coronary blood flow in
humans. Circulation. 1993;88:43-54.
26.
Treasure CB, Vita JA, Ganz P, Ryan TJ Jr, Schoen FJ,
Vekshtein VI, Yeung AC, Mudge GH, Alexander RW, Selwyn AP, Fish
RD. Loss of coronary microvasculature response to
acetylcholine in cardiac transplant patients.
Circulation. 1992;86:1156-1164.
27. Hruban RH, Beschorner WE, Baumgartner WA, Augustine SM, Ren H, Reitz BA, Hutchins GM. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol. 1991;137:871-882. [Abstract]
28. Hess HL, Hastillo A, Mohanakumar T, Crowley MJ, Vetrovac G, Szentpetery S, Wolfgang TC, Lower RR. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation. 1983;68(suppl II):II-94-II-101.
29. Petrossian GA, Nichols AB, Marboe CC, Sciacca R, Rose EA, Smith CR, Cannon PJ, Reemtsma K, Powers ER. Relationship between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation. 1989;80(suppl III):III-122-III-125.
30. Rose EA, Pepino P, Barr ML, Smith CR, Ratner AJ, Ho E, Berger C. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant. 1992;11:S120-S123. [Medline] [Order article via Infotrieve]
31. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 1992;339:1566-1570. [Medline] [Order article via Infotrieve]
32. Fullerton DA, Mitchell MB, McIntyre RC Jr, Brown JM, Meng X, Campbell DN, Grover FL. Mechanisms of coronary vasomotor dysfunction in the transplanted heart. Ann Thorac Surg. 1994;58:86-92. [Abstract]
33. Gaudin PB, Rayburn BK, Hutchins GM, Kasper EK, Baughman KL, Goodman SN, Lecks LE, Baumgartner WA, Hruban RH. Peritransplant injury to the myocardium associated with the development of accelerated arteriosclerosis in heart transplant recipients. Am J Surg Pathol. 1994;18:338-346. [Medline] [Order article via Infotrieve]
34. Meredith IT, Anderson TJ, Uehata A, Ryan TJ Jr, Mudge GH, Selwyn A, Ganz P, Yeung AC. Early endothelial dysfunction of the coronary endothelium after cardiac transplantation. Aust N Z J Med. 1992;22(suppl):45A. Abstract.
35. Anderson TJ, Meredith IT, Selwyn AP, Ganz P, Yeung AC. Early endothelial dysfunction does not predict the development of transplant coronary atherosclerosis. Can J Cardiol. 1993;9(suppl E):29E. Abstract.
36.
Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP,
Ganz P. Effect of cholesterol lowering and
anti-oxidant therapy on endothelium-dependent
coronary vasomotion. N Engl J Med. 1995;332:488-493.
37. Briscoe DM, Yeung AC, Schoen FJ, Allred EN, Stavrakis G, Ganz P, Cotran RS, Pober JS. Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. Transplantation. 1995;59:204-211. [Medline] [Order article via Infotrieve]
38.
De Lorgeril M, Boissonnat P, Mamelle N, Martin J-L,
Monjaud I, Guidollet J, Dureau G, Ninet J, Renaud S.
Platelet aggregation and HDL cholesterol are predictive
of acute coronary events in heart transplant
recipients. Circulation. 1994;89:2590-2594.
39.
Labarrere CA, Pitts D, Halbrook H, Faulk WP.
Tissue plasminogen activator,
plasminogen activator inhibitor-1,
and fibrin as indexes of clinical course in cardiac allograft
recipients: an immunocytochemical study.
Circulation. 1994;89:1599-1608.
40. Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant. 1989;8:349-359.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
P. Ganz, J. E. Ho, and P. Y. Hsue Structural and functional manifestations of human atherosclerosis: do they run in parallel? Eur. Heart J., July 1, 2009; 30(13): 1556 - 1558. [Full Text] [PDF] |
||||
![]() |
E. Raichlin, A. Prasad, W. K. Kremers, B. S. Edwards, C. S. Rihal, A. Lerman, and S. S. Kushwaha Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients Eur. Heart J., June 1, 2009; 30(11): 1356 - 1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ganz and P. Y. Hsue Individualized approach to the management of coronary heart disease identifying the nonresponders before it is too late. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 331 - 333. [Full Text] [PDF] |
||||
![]() |
B. P. Griffith, M. Haddad, and R. S. Poston Immunobiology of Heart and Heart-Lung Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1513 - 1538. [Full Text] |
||||
![]() |
L. W. Miller Coronary Microvasculopathy After Heart Transplantation: A New Marker to Guide Future Trials? Circulation, September 11, 2007; 116(11): 1224 - 1225. [Full Text] [PDF] |
||||
![]() |
R. N. Mitchell and P. Libby Vascular Remodeling in Transplant Vasculopathy Circ. Res., April 13, 2007; 100(7): 967 - 978. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahmani, R. P. Cruz, D. J. Granville, and B. M. McManus Allograft Vasculopathy Versus Atherosclerosis Circ. Res., October 13, 2006; 99(8): 801 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tanaka, K. Sydow, F. Gunawan, J. Jacobi, P. S. Tsao, R. C. Robbins, and J. P. Cooke Dimethylarginine Dimethylaminohydrolase Overexpression Suppresses Graft Coronary Artery Disease Circulation, September 13, 2005; 112(11): 1549 - 1556. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Vallbracht, P. L. Schwimmbeck, U. Kuhl, U. Rauch, B. Seeberg, and H.-P. Schultheiss Differential Aspects of Endothelial Function of the Coronary Microcirculation Considering Myocardial Virus Persistence, Endothelial Activation, and Myocardial Leukocyte Infiltrates Circulation, April 12, 2005; 111(14): 1784 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Wu and L. L. Wu Association of Soluble Markers with Various Stages and Major Events of Atherosclerosis Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 240 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Vallbracht, P. L. Schwimmbeck, U. Kuhl, B. Seeberg, and H.-P. Schultheiss Endothelium-Dependent Flow-Mediated Vasodilation of Systemic Arteries Is Impaired in Patients With Myocardial Virus Persistence Circulation, November 2, 2004; 110(18): 2938 - 2945. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Petrakopoulou, M. Kubrich, S. Pehlivanli, B. Meiser, B. Reichart, W. von Scheidt, and M. Weis Cytomegalovirus Infection in Heart Transplant Recipients Is Associated With Impaired Endothelial Function Circulation, September 14, 2004; 110(11_suppl_1): II-207 - II-212. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ganz and J. A. Vita Testing Endothelial Vasomotor Function: Nitric Oxide, a Multipotent Molecule Circulation, October 28, 2003; 108(17): 2049 - 2053. [Full Text] [PDF] |
||||
![]() |
S. Verma, M. R. Buchanan, and T. J. Anderson Endothelial Function Testing as a Biomarker of Vascular Disease Circulation, October 28, 2003; 108(17): 2054 - 2059. [Full Text] [PDF] |
||||
![]() |
Y. Oishi, Y. Nishimura, K.-i. Imasaka, N. Kajihara, S. Morita, M. Masuda, and H. Yasui Impairment of coronary flow reserve and left ventricular function in the brain-dead canine heart Eur. J. Cardiothorac. Surg., September 1, 2003; 24(3): 404 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hognestad, K. Endresen, R. Wergeland, O. Stokke, O. Geiran, T. Holm, S. Simonsen, J. K. Kjekshus, and A. K. Andreassen Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients J. Am. Coll. Cardiol., August 6, 2003; 42(3): 477 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Vassalli, A. Gallino, M. Weis, W. von Scheidt, L. Kappenberger, L.K. von Segesser, J.-J. Goy, and on behalf of the Working Group Microcirculation of Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy Eur. Heart J., July 1, 2003; 24(13): 1180 - 1188. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Lee, B. R. Wamhoff, L. C. Katwa, H. K. Reddy, D. J. Voelker, J. L. Dixon, and M. Sturek Increased Endothelin-Induced Ca2+ Signaling, Tyrosine Phosphorylation, and Coronary Artery Disease in Diabetic Dyslipidemic Swine Are Prevented by Atorvastatin J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 132 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Weis and J. P. Cooke Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 567 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Griffith and R. S. Poston Immunobiology of Heart and Heart-Lung Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1403 - 1426. [Full Text] |
||||
![]() |
C A J Farquharson and A D Struthers Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure Heart, December 1, 2002; 88(5): 475 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Alexander Oxidized LDL Autoantibodies, Endothelial Dysfunction, and Transplant-Associated Arteriosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1950 - 1951. [Full Text] [PDF] |
||||
![]() |
J. C. Fang, S. Kinlay, D. Behrendt, H. Hikita, J. L. Witztum, A. P. Selwyn, and P. Ganz Circulating Autoantibodies to Oxidized LDL Correlate With Impaired Coronary Endothelial Function After Cardiac Transplantation Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 2044 - 2048. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Wang, C. Dong, S. C. Stevenson, E. E. Herderick, J. Marshall-Neff, S. S. Vasudevan, N. I. Moldovan, R. E. Michler, N. R. Movva, and P. J. Goldschmidt-Clermont Overexpression of Soluble Fas Attenuates Transplant Arteriosclerosis in Rat Aortic Allografts Circulation, September 17, 2002; 106(12): 1536 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Yen, G. Pilkington, R. C. Starling, N. B. Ratliff, P. M. McCarthy, J. B. Young, G. M. Chisolm, and M. S. Penn Increased Tissue Factor Expression Predicts Development of Cardiac Allograft Vasculopathy Circulation, September 10, 2002; 106(11): 1379 - 1383. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kunze, S. Jeschkeit-Schubbert, S. Dahnken, J.H. Fischer, and S. Herzig Endothelial function after prolonged coronary artery oxygen persufflation in a rabbit model of heart preservation Interactive CardioVascular and Thoracic Surgery, September 1, 2002; 1(1): 16 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Vallbracht, P. L. Schwimmbeck, B. Seeberg, U. Kuhl, and H.-P. Schultheiss Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies J. Am. Coll. Cardiol., August 7, 2002; 40(3): 515 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Stoica, M. Goddard, and S. R. Large The endothelium in clinical cardiac transplantation Ann. Thorac. Surg., March 1, 2002; 73(3): 1002 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Marti, I. Romeo, R. Aymat, J. Garcia, P. Guiteras, M. Ballester, N. Aminian, J. M. Caralps, and J. M. Auge Coronary endothelial dysfunction as a predictor of intimal thickening in the long term after heart transplantation J. Thorac. Cardiovasc. Surg., December 1, 2001; 122(6): 1174 - 1180. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Melter, A. Exeni, M. E.J. Reinders, J. C. Fang, G. McMahon, P. Ganz, W. W. Hancock, and D. M. Briscoe Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Human Cardiac Allograft Rejection Circulation, November 20, 2001; 104(21): 2558 - 2564. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Stoica, D. K. Satchithananda, J. Dunning, and S. R. Large Two-decade analysis of cardiac storage for transplantation Eur. J. Cardiothorac. Surg., October 1, 2001; 20(4): 792 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Beckman, J. Ganz, M. A. Creager, P. Ganz, and S. Kinlay Relationship of Clinical Presentation and Calcification of Culprit Coronary Artery Stenoses Arterioscler. Thromb. Vasc. Biol., October 1, 2001; 21(10): 1618 - 1622. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Wildhirt, M. Weis, C. Schulze, N. Conrad, S. Pehlivanli, G. Rieder, G. Enders, W. von Scheidt, and B. Reichart Expression of Endomyocardial Nitric Oxide Synthase and Coronary Endothelial Function in Human Cardiac Allografts Circulation, September 18, 2001; 104 (2009): I-336 - I-343. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saitta, D. Altavilla, D. Cucinotta, N. Morabito, N. Frisina, F. Corrado, R. D'Anna, A. Lasco, G. Squadrito, A. Gaudio, et al. Randomized, Double-Blind, Placebo-Controlled Study on Effects of Raloxifene and Hormone Replacement Therapy on Plasma NO Concentrations, Endothelin-1 Levels, and Endothelium-Dependent Vasodilation in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1512 - 1519. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. von der Leyen and V. J. Dzau Therapeutic Potential of Nitric Oxide Synthase Gene Manipulation Circulation, June 5, 2001; 103(22): 2760 - 2765. [Full Text] [PDF] |
||||
![]() |
S. M. Wildhirt, M. Weis, C. Schulze, N. Conrad, S. Pehlivanli, G. Rieder, G. Enders, W. von Scheidt, and B. Reichart Coronary flow reserve and nitric oxide synthases after cardiac transplantation in humans Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 840 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Giulia Gagliardi, F Crea, B Polletta, C Bassano, G La Vigna, L Ballerini, and P Ragonese Coronary microvascular endothelial dysfunction in transplanted children Eur. Heart J., February 1, 2001; 22(3): 254 - 260. [Abstract] [PDF] |
||||
![]() |
E. Andriambeloson, M. Bigaud, E. O. Schraa, T. Kobel, V. Lobstein, C. Pally, and Hans-Gunter Zerwes Endothelial Dysfunction and Denudation in Rat Aortic Allografts Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 67 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhu, D. G. Kuhel, D. P. Witte, and D. Y. Hui Apolipoprotein E Inhibits Neointimal Hyperplasia after Arterial Injury in Mice Am. J. Pathol., December 1, 2000; 157(6): 1839 - 1848. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P. Perrault, F. Mahlberg, C. Breugnot, J.-P. Bidouard, N. Villeneuve, J.-P. Vilaine, and P. M. Vanhoutte Hypercholesterolemia Increases Coronary Endothelial Dysfunction, Lipid Content, and Accelerated Atherosclerosis After Heart Transplantation Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 728 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Dixon, J. D. Stoops, J. L. Parker, M. H. Laughlin, G. A. Weisman, and M. Sturek Dyslipidemia and Vascular Dysfunction in Diabetic Pigs Fed an Atherogenic Diet Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2981 - 2992. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Anderson Assessment and treatment of endothelial dysfunction in humans J. Am. Coll. Cardiol., September 1, 1999; 34(3): 631 - 638. [Full Text] [PDF] |
||||
![]() |
C. H. Spes, V. Klauss, H. Mudra, S. D. Schnaack, A. R. Tammen, J. Rieber, U. Siebert, K.-H. Henneke, P. Uberfuhr, B. Reichart, et al. Diagnostic and Prognostic Value of Serial Dobutamine Stress Echocardiography for Noninvasive Assessment of Cardiac Allograft Vasculopathy : A Comparison With Coronary Angiography and Intravascular Ultrasound Circulation, August 3, 1999; 100(5): 509 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P Perrault, J.-P. Bidouard, P. Janiak, N. Villeneuve, P. Bruneval, J.-P. Vilaine, and P. M Vanhoutte Impairment of G-protein-mediated signal transduction in the porcine coronary endothelium during rejection after heart transplantation Cardiovasc Res, August 1, 1999; 43(2): 457 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Verhaar, M. L.H. Honing, T. van Dam, M. Zwart, H. A. Koomans, J. J.P. Kastelein, and T. J. Rabelink Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids Cardiovasc Res, June 1, 1999; 42(3): 752 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Veeramachaneni, A. H. Harken, and C. B. Cairns Clinical Implications of Hemoglobin as a Nitric Oxide Carrier Arch Surg, April 1, 1999; 134(4): 434 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ghiadoni, S. Taddei, A. Virdis, I. Sudano, V. Di Legge, M. Meola, L. Di Venanzio, and A. Salvetti Endothelial Function and Common Carotid Artery Wall Thickening in Patients With Essential Hypertension Hypertension, July 1, 1998; 32(1): 25 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. T. Aretz and R. B. Colvin Endomyocardial Biopsies: An Early Warning System for Chronic Transplant Arteriopathy JAMA, October 8, 1997; 278(14): 1197 - 1198. [Abstract] [PDF] |
||||
![]() |
M. Weis and W. von Scheidt Cardiac Allograft Vasculopathy : A Review Circulation, September 16, 1997; 96(6): 2069 - 2077. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |